

Joseph A Nicolazzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2866093/publications.pdf>

Version: 2024-02-01

81
papers

3,233
citations

201674

27
h-index

155660

55
g-index

82
all docs

82
docs citations

82
times ranked

4709
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial A β . <i>Neuron</i> , 2008, 59, 43-55.	8.1	629
2	Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (\hat{a})-epigallocatechin gallate. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 41, 219-225.	4.0	243
3	Buccal penetration enhancersâ€”How do they really work?. <i>Journal of Controlled Release</i> , 2005, 105, 1-15.	9.9	169
4	Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution. <i>Food Chemistry</i> , 2010, 122, 662-667.	8.2	167
5	Chitosan nanoparticles enhance the plasma exposure of (\hat{a})-epigallocatechin gallate in mice through an enhancement in intestinal stability. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 422-426.	4.0	129
6	Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain. <i>PLoS ONE</i> , 2013, 8, e59749.	2.5	116
7	Enhancing the Buccal Mucosal Delivery of Peptide and Protein Therapeutics. <i>Pharmaceutical Research</i> , 2015, 32, 1-21.	3.5	94
8	Methods to assess drug permeability across the blood-brain barrier. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 58, 281-293.	2.4	91
9	Fatty Acid-Binding Protein 5 Facilitates the Bloodâ€”Brain Barrier Transport of Docosahexaenoic Acid. <i>Molecular Pharmaceutics</i> , 2015, 12, 4375-4385.	4.6	88
10	Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2018, 135, 62-74.	13.7	78
11	The Effect of Various In Vitro Conditions on the Permeability Characteristics of the Buccal Mucosa. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 2399-2410.	3.3	77
12	Fatty Acid-Binding Protein 5 at the Bloodâ€”Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function. <i>Journal of Neuroscience</i> , 2016, 36, 11755-11767.	3.6	61
13	Assessment of the effects of sodium dodecyl sulfate on the buccal permeability of caffeine and estradiol. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 431-440.	3.3	54
14	Altered Brain Uptake of Therapeutics in a Triple Transgenic Mouse Model of Alzheimerâ€™s Disease. <i>Pharmaceutical Research</i> , 2013, 30, 2868-2879.	3.5	53
15	The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in Rats. <i>Molecular Pharmaceutics</i> , 2014, 11, 496-504.	4.6	49
16	Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2). <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 130-147.	2.1	48
17	Memantine Transport across the Mouse Bloodâ€”Brain Barrier Is Mediated by a Cationic Influx H ⁺ Antiporter. <i>Molecular Pharmaceutics</i> , 2013, 10, 4491-4498.	4.6	48
18	Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide. <i>Journal of Controlled Release</i> , 2005, 105, 240-248.	9.9	46

#	ARTICLE	IF	CITATIONS
19	Synthesis, Structure-Activity Relationships and Brain Uptake of a Novel Series of Benzopyran Inhibitors of Insulin-Regulated Aminopeptidase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1368-1377.	6.4	46
20	Modification of buccal drug delivery following pretreatment with skin penetration enhancers. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2054-2063.	3.3	39
21	Synergistic enhancement of testosterone transdermal delivery. <i>Journal of Controlled Release</i> , 2005, 103, 577-585.	9.9	37
22	Impact of P-Glycoprotein Inhibition and Lipopolysaccharide Administration on Blood-Brain Barrier Transport of Colistin in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 502-507.	3.2	37
23	The Impact of Docosahexaenoic Acid on Alzheimer's Disease: Is There a Role of the Blood-Brain Barrier?. <i>Current Clinical Pharmacology</i> , 2015, 10, 222-241.	0.6	37
24	Brain Penetration of Colistin in Mice Assessed by a Novel High-Performance Liquid Chromatographic Technique. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4247-4251.	3.2	35
25	Drug Access to the Central Nervous System in Alzheimer's Disease: Preclinical and Clinical Insights. <i>Pharmaceutical Research</i> , 2015, 32, 819-839.	3.5	34
26	Cognitive benefits of lithium chloride in APP/PS1 mice are associated with enhanced brain clearance of β -amyloid. <i>Brain, Behavior, and Immunity</i> , 2018, 70, 36-47.	4.1	34
27	Species-Dependent Blood-Brain Barrier Disruption of Lipopolysaccharide: Amelioration by Colistin <i>In Vitro</i> and <i>In Vivo</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4336-4342.	3.2	29
28	Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1 [R14A] for the Treatment of Autoimmune Diseases. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 650-656.	3.3	27
29	Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases. <i>Journal of Controlled Release</i> , 2015, 199, 37-44.	9.9	26
30	Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease. <i>Molecular Pharmaceutics</i> , 2018, 15, 4073-4083.	4.6	23
31	The Buccal Mucosa as an Alternative Route for the Systemic Delivery of Risperidone. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 4584-4592.	3.3	21
32	Computational Prediction of CNS Drug Exposure Based on a Novel <i>In Vivo</i> Dataset. <i>Pharmaceutical Research</i> , 2012, 29, 3131-3142.	3.5	21
33	A Novel Flow through Diffusion Cell for Assessing Drug Transport across the Buccal Mucosa <i>In Vitro</i> . <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4577-4588.	3.3	18
34	The Involvement of a Na ⁺ - and Cl ⁻ -Dependent Transporter in the Brain Uptake of Amantadine and Rimantadine. <i>Molecular Pharmaceutics</i> , 2012, 9, 883-893.	4.6	18
35	Fatty Acid-Binding Protein 5 Mediates the Uptake of Fatty Acids, but not Drugs, Into Human Brain Endothelial Cells. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1185-1193.	3.3	18
36	Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega-3 fatty acid diets. <i>Journal of Neurochemistry</i> , 2018, 144, 81-92.	3.9	18

#	ARTICLE	IF	CITATIONS
37	The flavonoid, 2-ethoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1266-1282.	4.3	18
38	Altered blood-brain barrier and blood-spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety. <i>British Journal of Pharmacology</i> , 2022, 179, 2577-2588.	5.4	18
39	Enhanced Buccal Mucosal Retention and Reduced Buccal Permeability of Estradiol in the Presence of Padimate O and Azone: A Mechanistic Study. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 873-882.	3.3	17
40	Assessment of plasma concentrations of (â)-epigallocatechin gallate in mice following administration of a dose reflecting consumption of a standard green tea beverage. <i>Food Chemistry</i> , 2011, 128, 7-13.	8.2	17
41	Effect of Systemic Infection Induced by <i>Pseudomonas aeruginosa</i> on the Brain Uptake of Colistin in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5240-5246.	3.2	17
42	Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2173-2179.	3.3	17
43	The Effect of Formulation Excipients on the Penetration and Lateral Diffusion of Ibuprofen on and within the Stratum Corneum Following Topical Application to Humans. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 909-919.	3.3	16
44	Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access. <i>AAPS Journal</i> , 2017, 19, 940-956.	4.4	16
45	Ionophore and Biometal Modulation of P-glycoprotein Expression and Function in Human Brain Microvascular Endothelial Cells. <i>Pharmaceutical Research</i> , 2018, 35, 83.	3.5	16
46	Effect of Permeation Enhancers on the Buccal Permeability of Nicotine: Ex vivo Transport Studies Complemented by MALDI MS Imaging. <i>Pharmaceutical Research</i> , 2018, 35, 70.	3.5	16
47	Transport of drugs across the blood-brain barrier in Alzheimer's disease. <i>Therapeutic Delivery</i> , 2010, 1, 595-611.	2.2	15
48	Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated Î²-Amyloid and Inhibits the Formation of Neurotoxic Oligomers. <i>Journal of Biological Chemistry</i> , 2016, 291, 547-559.	3.4	15
49	Quantitation of Polymyxin-Lipopolysaccharide Interactions Using an Image-Based Fluorescent Probe. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1006-1010.	3.3	15
50	The hyperpolarization-activated cyclic nucleotide-gated 4 channel as a potential anti-seizure drug target. <i>British Journal of Pharmacology</i> , 2020, 177, 3712-3729.	5.4	14
51	Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them?. <i>Frontiers in Oncology</i> , 2021, 11, 718590.	2.8	14
52	Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2484-2489.	3.3	13
53	Pioglitazone Increases Blood-Brain Barrier Expression of Fatty Acid-Binding Protein 5 and Docosahexaenoic Acid Trafficking into the Brain. <i>Molecular Pharmaceutics</i> , 2020, 17, 873-884.	4.6	13
54	Development and Validation of an In-Cell Western for Quantifying P-Glycoprotein Expression in Human Brain Microvascular Endothelial (hCMEC/D3) Cells. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2614-2624.	3.3	12

#	ARTICLE	IF	CITATIONS
55	Lysine to arginine mutagenesis of chlorotoxin enhances its cellular uptake. <i>Biopolymers</i> , 2017, 108, e23025.	2.4	12
56	Biodistribution of polymer hydrogel capsules for the delivery of therapeutics. <i>Acta Biomaterialia</i> , 2012, 8, 3251-3260.	8.3	11
57	Azone® Decreases the Buccal Mucosal Permeation of Diazepam in a Concentration-Dependent Manner via a Reservoir Effect. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1133-1141.	3.3	11
58	Dietary docosahexaenoic acid supplementation enhances expression of fatty acid-binding protein 5 at the blood-brain barrier and brain docosahexaenoic acid levels. <i>Journal of Neurochemistry</i> , 2018, 146, 186-197.	3.9	11
59	Exploiting the Buccal Mucosa as an Alternative Route for the Delivery of Donepezil Hydrochloride. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1643-1651.	3.3	10
60	Assessing the Impact of Lithium Chloride on the Expression of P-Glycoprotein at the Blood-Brain Barrier. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2625-2631.	3.3	10
61	Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimer's Disease. <i>Molecular Pharmaceutics</i> , 2020, 17, 1527-1537.	4.6	10
62	Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides. <i>International Journal of Pharmaceutics</i> , 2021, 599, 120398.	5.2	10
63	Nitrile-Functionalized Poly(2-oxazoline)s as a Versatile Platform for the Development of Polymer Therapeutics. <i>Biomacromolecules</i> , 2021, 22, 4618-4632.	5.4	10
64	Brain uptake of diazepam and phenytoin in a genetic animal model of absence epilepsy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2010, 37, 647-649.	1.9	9
65	Reduced CNS exposure of memantine in a triple transgenic mouse model of Alzheimer's disease assessed using a novel LC-MS technique. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 85, 198-206.	2.8	9
66	Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner. <i>Pharmaceutical Research</i> , 2015, 32, 3432-3446.	3.5	9
67	Blockade of Microglial Kv1.3 Potassium Channels by the Peptide HsTX1 [R14A] Attenuates Lipopolysaccharide-mediated Neuroinflammation. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 638-647.	3.3	9
68	Copper bis(thiosemicarbazone) complexes modulate P-glycoprotein expression and function in human brain microvascular endothelial cells. <i>Journal of Neurochemistry</i> , 2022, , .	3.9	9
69	Decreased blood-brain barrier expression of P-glycoprotein in Alzheimer's disease: impact on pathogenesis and brain access of therapeutic agents. <i>Therapeutic Delivery</i> , 2011, 2, 841-844.	2.2	7
70	Development of a Vertically Integrated Pharmacy Degree. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 156.	1.6	7
71	Prolonged Plasma Exposure of the Kv1.3-Inhibitory Peptide HsTX1 [R14A] by Subcutaneous Administration of a Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere Formulation. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1182-1188.	3.3	6
72	The Effects of Clioquinol on P-glycoprotein Expression and Biometal Distribution in the Mouse Brain Microvasculature. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2247-2255.	3.3	5

#	ARTICLE	IF	CITATIONS
73	Lipopolysaccharide influences the plasma and brain pharmacokinetics of subcutaneously-administered HsTX1 [R14A], a KV1.3-blocking peptide. <i>Toxicon</i> , 2021, 195, 29-36.	1.6	5
74	A Tribute to Ronald T. Borchardt—Teacher, Mentor, Scientist, Colleague, Leader, Friend, and Family Man. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 370-385.	3.3	4
75	A Combination of Cloiquinol, Zinc and Copper Increases the Abundance and Function of Breast Cancer Resistance Protein in Human Brain Microvascular Endothelial Cells. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 338-346.	3.3	4
76	Potential Mechanism of Cellular Uptake of the Excitotoxin Quinolinic Acid in Primary Human Neurons. <i>Molecular Neurobiology</i> , 2021, 58, 34-54.	4.0	4
77	Increasing Intracellular Levels of Iron with Ferric Ammonium Citrate Leads to Reduced P-glycoprotein Expression in Human Immortalised Brain Microvascular Endothelial Cells. <i>Pharmaceutical Research</i> , 2021, 38, 97-111.	3.5	4
78	Altered peripheral factors affecting the absorption, distribution, metabolism, and excretion of oral medicines in Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114282.	13.7	4
79	Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2351-2359.	2.4	3
80	Development and validation of a LC-MS/MS assay for quantifying the uptake of docosahexaenoic acid-d5 into mouse microglia. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 191, 113575.	2.8	2
81	Commentary on the 2018 Named Series on blood-brain interfaces: Roles of neuroimmunomodulation in health and disease. <i>Brain, Behavior, and Immunity</i> , 2018, 74, 3-6.	4.1	1